People with weakened immune systems might not develop enough immunity after vaccination with two doses of an mRNA COVID-19 vaccine. The CDC recommends an additional primary shot of an mRNA COVID-19 vaccine (at least 28 days after the second dose) for some people with weakened immune systems, such as those who have had an organ transplant. Two doses are needed for ages 6 months through age 17, four to eight weeks apart Two doses are needed for ages 18 and up, 28 days apart (or up to six weeks apart, if needed) in the U.S. The bivalent booster can be given at least two months after the last shot. People age 5 and older who have a weakened immune system and have had all recommended doses of a COVID-19 vaccine can get an updated, or bivalent, booster dose of the Pfizer-BioNTech COVID-19 vaccine. People 18 and older may also get a Novavax booster based on the original virus strain six months after their last shot. People can get the booster shot at least two months after their last shot. People age 6 and older can choose between the Pfizer-BioNTech and the Moderna COVID-19 bivalent vaccine booster. People ages 5 and older who had all recommended doses of a COVID-19 vaccine can get the Pfizer-BioNTech COVID-19 updated, or bivalent, booster. An additional primary shot might improve their protection against the COVID-19 virus. The CDC recommends an additional primary shot of an mRNA COVID-19 vaccine (at least 28 days after the second dose) for some people age 5 and older with weakened immune systems, such as those who have had an organ transplant. Some protection provided after the first dose Three doses are needed for age 6 months through age 4, with the first two shots given 3 to 8 weeks apart and the third shot at least eight weeks after the second shot For immunocompromised individuals 6 years of age and older, a single additional age-appropriate dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine additional age-appropriate doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.Two doses are needed, 21 days apart (or up to six weeks apart, if needed) in the U.S.For immunocompromised individuals 6 months through 5 years of age who have received two doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), a single additional dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 1 month following the most recent dose of Moderna COVID-19 Vaccine, Bivalent additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.Immunocompromised individuals 6 months of age and older: Individuals 65 years of age and older who have received one dose of a bivalent COVID-19 vaccine: A dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 4 months after the dose of the bivalent COVID-19 vaccine.Individuals who have received one or more doses of a monovalent COVID-19 vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 2 months after any monovalent COVID-19 vaccine.Unvaccinated individuals: A single dose of Moderna COVID-19 Vaccine, Bivalent.Individuals who have received two doses of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 2 months after the last dose of Moderna COVID-19 Vaccine.Individuals who have received one dose of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered 1 month after the dose of Moderna COVID-19 Vaccine.The second dose is administered 1 month after the first. Unvaccinated individuals: Two doses of Moderna COVID-19 Vaccine, Bivalent are administered.Individuals 6 months through 5 years of age:
Moderna COVID-19 Vaccine, Bivalent is now authorized for use as follows: The monovalent Moderna COVID-19 Vaccine is no longer authorized for use in the United States. This action includes authorizing the current bivalent vaccine (Original and Omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older. On April 18, 2023, the Food and Drug Administration amended the emergency use authorization (EUA) of Moderna COVID-19 Vaccine, Bivalent to simplify the vaccination schedule for most individuals. Fact Sheets Fact Sheet Translations Vacunas contra el COVID-19
0 kommentar(er)
